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Introduction: Oncolytic virus therapy is a promising therapy for 
numerous tumor types. Edmonston-strain measles virus (MV) has 
been tested in clinical trials for ovarian cancer, glioma, and myeloma. 
Therefore, the antitumor activity of MV against non–small-cell lung 
cancer (NSCLC) was assessed.
Methods: Human NSCLC cells and immortalized lung epithelial 
cell lines, Beas2B, were infected with either MV-producing green 
fluorescent protein or MV-producing carcinoembryonic antigen. 
Cells were assessed for viability, induction of apoptosis by caspase 
and poly-ADP ribose polymerase cleavage, and for viral transgene 
production. The dependency of MV entry on CD46 and nectin-4 
were determined using blocking antibodies. The role of host trans-
lational activity on viral replication was assessed by overexpres-
sion of eIF4E and translation inhibition. Antitumor activity was 
assessed by measuring treated NSCLC xenografts from flanks of 
nude mice.
Results: MV infection of NSCLC cells results in potent cell killing 
in most of the cell lines compared with immortalized Beas2B cells 
and induces apoptosis. MV infection was prevented by blocking of 
CD46, however independent of nectin-4 blockade. Tumor weights are 
diminished after intratumoral injections of MV-producing carcino-
embryonic antigen in one of two cell lines and result in detectable 
viral transgene in serum of mice.
Conclusions: These data indicate that MV is oncolytic for 
human NSCLC and this was independent of nectin-4 expres-
sion. Dysregulated protein translational machinery may play 
a role in determining tumor tropism in NSCLC. MV combined 
with gemcitabine could be explored further as chemovirotherapy 
for NSCLC.
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(J Thorac Oncol. 2014;9: 1101–1110)
Non–small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide.1 Despite recent 
advances in targeted therapy, long-term survival of patients 
with NSCLC remains dismal. Novel treatment approaches are 
needed to extend survival of these patients and improve con-
trol of this disease.
Utilizing the tumor tropic properties of certain live-rep-
licating viruses has garnered attention recently.2,3 Edmonston 
strains of measles virus (MV) are promising oncolytic viruses 
as the MV receptor, CD46, is often overexpressed on many 
tumor tissues, resulting in more selective infection in cancer 
cells.4 Moreover, abnormalities in the innate antiviral response 
in cancer cells allow for viral replication and spread selec-
tively within tumors.5 At doses used for vaccination, MV 
has a strong track record of safe use in humans, making it an 
excellent candidate virus for clinical translation. Furthermore, 
the MV genome can accommodate insertion or deletion of 
genetic material, allowing for MV to serve as a platform for 
novel recombinant viral gene therapy.
Previous work has demonstrated clear oncolytic effects 
of MV in many cancer types. A phase I trial was recently com-
pleted in heavily pretreated patients with ovarian cancer with 
promising results.6 Importantly, there was minimal toxicity 
seen. All patients on the study were previously immunized 
against MV; however, the neutralizing antibody titer remained 
relatively stable throughout the study.
Though there are some prior data on the effects of differ-
ent strains of MV on NSCLC cells,7,8 there are little data regard-
ing the MV strains used in clinical trials on NSCLC. Expression 
of CD46 has been previously documented in as high as 40% of 
NSCLC tumors;9 therefore, MV could be a therapeutic agent 
appropriate for clinical translation in NSCLC. In the present 
manuscript, data are presented that show the anticancer activity 
of an Edmonston-strain MV virus against NSCLC. These data 
show that MV replicates within NSCLC cells and in human 
xenografts and induces apoptosis. These results also show that 
part of the tumor tropism of MV for cancer cells may be deter-
mined by constitutively activated protein translation in NSCLC.
MATERIALS AND METHODS
Cell Lines and Reagents
Immortalized Beas2B cells and NSCLC cells, H460, 
A549, H838, H520, H522, H2009, H2030, and murine Lewis 
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lung cancer (LLC) were obtained from the ATCC. Human 
bronchial epithelial cells immortalized with CDK4 and hTERT 
were provided by John Minna, MD, PhD (UT Southwestern). 
Human bronchial epithelial cells were cultured with keratino-
cyte serum-free media (Life Technologies Inc., Grand Island, 
NY) containing 50 μg/ml of bovine pituitary extract (Life 
Technologies Inc.) and 5 ng/ml of epidermal growth factor 
(EGF) (Life Technologies Inc.). Beas2B cells were grown 
in keratinocyte serum-free media with 5 pg/ml human EGF 
and 0.05 mg/ml bovine pituitary extract (Gibco, Invitrogen). 
NSCLC cells were grown in RPMI 1640 supplemented with 
10% calf serum (Biofluids) (R10). H838 cells were grown 
with R10 supplemented with 10 mM HEPES, 1 mM sodium 
pyruvate, 4.5 g/liter glucose, and 1.5 g/liter sodium bicarbon-
ate. LLC cells were grown with DMEM media supplemented 
with 10% calf serum. The authenticity of these cell lines were 
verified by short tandem repeat analysis (Johns Hopkins). 
Rapamycin (EMD Millipore, Billerica, MA) and 4EGI-1 
(Chembridge Corp., San Diego, CA) were dissolved in 100% 
DMSO, aliquoted, and stored at −20°C until used. Gemcitabine 
(Eli Lilly and Co., Indianapolis, IN) was dissolved in 1X phos-
phate-buffered saline (PBS) and stored at room temperature.
Viral Vectors
MV bearing the gene that encodes green fluorescent 
protein (MV-GFP) or human CEA (carcinoembryonic antigen; 
MV-CEA) were constructed and propagated as described.10 
The titer was determined by 50% end-point dilution assays 
([TCID
50
]/ml) on Vero cells and stored at −80°C as described.11
Cell Transfection
Beas2B were transfected with previously described 
pMSCV-M1GR1 constructs,12 either encoding or not encod-
ing HA-tagged translational regulator eIF4E from mouse, 
linked to GFP. GFP-positive cells were sorted on a FACS 
DiVA (BD Biosciences, Franklin Lakes, NJ). Immunoblots 
for HA-tagged eIF4E were performed on cell lysates to con-
firm the presence of the transgene.
In vitro Cap-Affinity Assay
The strength of cap-mediated complex formation was 
measured using cap-affinity assay as described.13 Lysate from 
Beas2B cells that either do or do not produce exogeneous 
HA-tagged mouse eIF4E were diluted in lysis buffer and com-
bined with 7-methyl GTP-Sepharose4B (GE Life Sciences, 
Piscataway, NJ) and incubated while mixing for two hours 
at 4°C. 100 μM 7-methylguanosine 5’-triphosphate (Sigma-
Aldrich) was employed to elute eIF4E from the 7-methyl 
GTP-Sepharose4B beads. The eluted samples were then pre-
pared for immunoblot analysis.
Immunoblot Analysis
Protein samples for the cap-affinity assay were separated 
by 8 to 15% gradient SDS-PAGE (polyacrylamide gel electro-
phoresis). Ten, twelve, or fifteen percent SDS-PAGE was used 
for other immunoblots as previously described.13 The primary 
antibodies employed were rabbit α-eIF4E, rabbit α-4E-BP1, 
rabbit α-poly-ADP ribose polymerase (PARP), α-eIF2α, 
α-phospho-eIF2α(Ser51), α-PKR, α-phospho-PKR, all from 
Cell Signaling at a 1:1000 dilution, mouse α-b-actin (Sigma) 
at a 1:10,000 dilution, and rabbit α-eIF4GI (kindly provided 
by Nahum Sonenberg, McGill University Montreal, Quebec, 
Canada) at a 1:2500 dilution. Detection was performed using 
ECL Plus Western Blotting System (Pierce) to visualize the 
bands of interest.
Viral Infection and Cell Viability Assays
Beas2B and NSCLC cells were seeded at 105 cells per 
well in six well plates. After overnight incubation, the cells 
were washed with Opti-MEM (Gibco) and then infected with 
MV-GFP or MV-CEA at different multiplicities of infection 
(MOI) (0.1, 0.5, 1.0) in 0.4 ml of Opti-MEM for 2 hours at 
37°C. Complete medium for each cell line was then added to 
the wells for the duration of the treatment. For cells treated 
with MV-GFP, viral syncytia were visualized and photo-
graphed using light and fluorescence microscopy.
For combination treatments, cells (105 cells/well) were 
infected with MV-GFP at an MOI of 0.01. Rapamycin (Sigma) 
was used at a concentration of 50 nM, gemcitabine was used at a 
concentration of 25 nM, and 4EGI-1 was used at a concentration 
of 15 μM. Controls were treated with equal volumes of the drug’s 
vehicle (DMSO or PBS, respectively). Cells were counted by 
trypan blue exclusion by using a hemacytometer 72 hours after 
infection for all cell viability assays. Cell survival is expressed 
as cell number normalized to untreated cells. Each experiment 
was performed in triplicate. For experiments employed to deter-
mine combination indices, 7500 cells/well were seeded onto 
96-well plates. After overnight incubation, cells were treated 
with MV-GFP at an MOI of 0.1 and 0.25, and treated with vary-
ing concentrations of rapamaycin or 4EGI-1 alone and with dif-
ferent combinations for 72 hours. All treatments were done in 
triplicate and analyzed for viable cells by CCK-8 assay (Dojindo 
Molecular Technologies, Inc., Rockville, MD).
CEA Level Determination
Beas2B and NSCLC cells were treated with the indi-
cated MOI of MV-CEA. Seventy-two hours later, conditioned 
medium was collected from cells and analyzed for CEA. 
The CEA levels were measured using CEA ELISA kit (Bio-
Quant, Inc., Nashville, TN) as per manufacturer’s instructions. 
Samples were analyzed in triplicate with both positive and 
negative controls included.
Apoptosis Assays
Apoptosis was assessed by immunoblot assay for PARP 
cleavage. In addition, caspase-3 and -7 activities were measured 
using the Caspase-Glo 3/7 assay kit (Promega, Madison, WI) as 
per instructions provided by manufacturer. Cells were treated 
with MV-GFP at an MOI of 1.0 in Opti-MEM. Two hours later, 
complete growth medium was added to the cells and cells 
were incubated at 37°C. After 48 hours of incubation, lumi-
nescence for each sample was measured after 1 hour incuba-
tion in Caspase-Glo reagent using a plate-reading luminometer 
(FLUOstar Omega from BMG Labtech). Background lumi-
nescence of blank wells was subtracted from the luminescence 
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of sample wells. Caspase activity was normalized to untreated 
cells. These experiments were performed in triplicate.
Flow Cytometry
NSCLC cells were washed in PBS containing 1% BSA 
(PBS-BSA), centrifuged, and resuspended in PBS-BSA. Cells 
were then incubated for 30 minutes at 4°C with phycoery-
thrin (PE) CD46 antibody (Abcam), anti-Nectin-4-PE (R & 
D Systems, FAB2659), or control isotype-IgG-PE antibody 
(Invitrogen), centrifuged, and resuspended in PBS-BSA. 
Cells were analyzed for CD46 and Nectin-4 levels on a Bectin 
Dickinson FACS Calibur cytometer. Analysis was done using 
FlowJo software (Treestar).
Blocking of CD46 and Nectin-4
104 H2009 cells were seeded onto 96-well plates in 
Opti-MEM. The next day, cells were treated with Isotype IgG 
(R & D systems, AB-108-C), nectin-4 IgG (R & D systems, 
AF2659),14 CD46 IgG (Santa Cruz, sc-5267-clone m177), or 
both nectin-4 and CD46 Abs at a concentration of 100 μg/ml. 
One hour after addition of the antibodies, MV-GFP was added 
to the wells at an MOI of 1.0. After 2 hours of infection, R10 
media were added to the wells and cells were incubated for 48 
hours. Cells were analyzed by fluorescence microscopy at 48 
hours and photomicrographs were taken. In parallel, fluores-
cence was quantified using a 96-well plate reader. Cells were 
treated in triplicate. Uninfected cells and MV-GFP infected 
cells without blocking antibodies were used as negative and 
positive controls, respectively. Experiment was repeated 
two times.
Animal Experiments
All animal experiments were performed in concor-
dance with Institutional Animal Care and Use Committee 
approved protocols at the University of Minnesota (Protocol 
#: 1103A97372). Nude mice were injected in the flank with 
2.5 × 106 A549 or 3.5 × 106 H2009 cells. When tumors were 
0.5 cm3, they were injected with 8.4 × 105 MV-CEA twice 
weekly for 3 weeks for a total of 6 intratumoral treatments. 
Tumors were measured in two dimensions weekly and tumor 
volume was estimated using the following equation: [long 
diameter × (short diameter2)]/2. Mice were weighed weekly. 
Blood was collected from mice for CEA determination. Whole 
blood was collected in ethylenediaminetetraacetic acid-treated 
tubes (BD Bioscience), inverted to mix, centrifuged (1500 × g), 
and plasma was collected and stored at -80°C until further 
analysis. Animals were killed 1 week after the last dose of 
MV-CEA using CO
2
 euthanasia. Tumors were excised and 
weighed. Ten mice were treated per cohort.
Statistical Analysis
Data are presented as means and error bars are standard 
deviation or standard error of the mean as indicated. Differences 
between groups were compared using two-sided t tests. A p 
value of less than 0.05 was significant. Synergy of MV with 
4EGI-1 or rapamycin was analyzed by the method of Chou and 
Talalay15 using Compusyn (ComboSyn, Inc., Paramus, NJ).
RESULTS
The expression of the MV receptor, CD46, on NSCLC 
cell lines were compared with immortalized lung epithelial 
cells (Beas2B). Although all the cells express CD46, the lev-
els of CD46 were higher in H838, H2030, A549, and H460 
cells than Beas2B, whereas levels were comparable for the 
other cell lines tested (Fig. 1A, B). Nectin-4 is expressed in 
up to 58% of NSCLC tumors and its expression is associated 
with a poorer prognosis.16 Nectin-4 has recently been identi-
fied as a receptor for MV, and therefore, we were interested 
to further evaluate the importance of nectin-4 expression in 
determining MV infection.14,17 Of the cell lines tested, nec-
tin-4 was highly expressed only in H838 and H2009 cells 
(Fig. 1C, D). To further analyze the importance of nectin-4 
and CD46 in mediating viral entry, H2009 cells were treated 
with blocking antibodies against nectin-4, CD46, or both. 
Isotype IgG antibodies were used as a control. Cells were 
then infected with MV-GFP. Blocking nectin-4 had virtually 
no effect on viral infection in H2009. On the contrary, block-
ing CD46 resulted in near-complete inhibition of MV-GFP 
infection (Fig. 1E, F). Blocking of both receptors did not 
yield different results from blocking of CD46. These results 
suggest that on H2009 cells that express nectin-4, MV-GFP 
viral entry depends upon CD46.
After treatment of cells with MV-GFP, growth inhibi-
tory effects were seen in all cell lines tested in a dose-depen-
dent manner (Fig. 2A). Beas2B and H838 cells were relatively 
resistant to the cytotoxic effects of MV at all MOI tested. The 
rest of the cell lines tested were inhibited by MV treatment in 
vitro. Syncytia were visible by fluorescence microscopy at 24 
hours and visibly increased daily at all MOI tested (Fig. 2B), 
demonstrating that MV is able to enter and replicate within 
NSCLC cells. Separate experiments were performed using 
MV-CEA, and the CEA levels were detected by enzyme-linked 
immunosorbent assay from treated supernatants 72 hours after 
infection. Each of the infected NSCLC cell lines robustly pro-
duced CEA several thousand-fold greater than untreated cells, 
indicating that the CEA measured was representative of viral 
infection (Fig. 2C).
We next examined the mechanism by which MV 
induces death of the NSCLC cells. Viral infection often 
induces the cellular apoptotic response.18 Poly-ADP Ribose 
Polymerase (PARP) cleavage was assessed in NSCLC cells 
treated with MV or control as an indicator for induction of 
apoptosis (Fig. 3A). PARP cleavage was induced for all of 
the NSCLC cell lines tested by 48 hours posttreatment. PARP 
cleavage was most pronounced in H2009 and A549 and to a 
lesser degree in H2030 and H838 cells. The same cells were 
assayed for Caspase 3/7 cleavage, which is an earlier indica-
tor of apoptosis. Similar results were obtained for the cell 
lines tested (Fig. 3B). Despite being relatively resistant to 
MV, H838 cells did undergo a three-fold increase in caspase 
3/7 activity after MV infection; however, PARP cleavage was 
fairly minimal. It is unclear why there was this discrepancy; 
however, PARP cleavage is downstream of caspase 3/7 activa-
tion.19–21 Therefore, it is conceivable that these cells harbor a 
defect in the execution phase of the apoptotic program; how-
ever, this is speculative.
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Next, to determine the activity of MV against human 
NSCLC, we tested the effects of MV in nude mouse xenografts. 
NSCLC xenografts were grown in the flanks of nude mice and 
given intratumoral injections of MV-CEA twice weekly for 3 
weeks. All mice were kiled 4 weeks after initial treatment and 
tumors were excised and weighed (Fig. 4A, B). Intratumoral 
injections of MV-CEA resulted in substantial activity against 
H2009 tumors, resulting in markedly decreased tumor growth 
compared with controls (p < 0.0001). H2009 tumor weights 
were substantially decreased by MV treatment. The results 
with the A549 xenografts were modest and there was no signif-
icant difference in measured tumor volumes. However, there 
was separation of the growth curves that was evident by the 
end of treatment and excised tumors were smaller (p < 0.05). 
Because mice are not hosts for MV infection and do not make 
CEA, the sera of mice was assayed for CEA as an indicator of 
viral infection. In A549, the CEA in the blood quantitatively 
increased with each week of treatment, suggesting that the 
virus was able to replicate and had sustained throughout the 
treatment period (Fig. 4C). H2009 cells also had detectable 
CEA in the serum at the time of sacrifice 1 week after com-
pleting treatment with MV-CEA (data not shown). Human 
NSCLC express CEA as well.22 At later time points, there was 
some CEA detectable in the serum of control mice; however, 
it was greater than 3000-fold higher in MV-CEA-treated mice, 
suggesting that the majority of CEA detected was representa-
tive of viral transgene.
One of the hallmarks of innate antiviral defenses is 
to inhibit viral protein synthesis by disabling translational 
initiation pathways. Because NSCLC is characterized by 
deregulated, constitutively active translation, this defect may 
promote viral replication and account for the tropism of onco-
lytic viruses for NSCLC.23 First, the effect of MV infection on 
factors regulating protein translation was assayed by immu-
noblot. The levels of eukaryotic initiation factor 4G (eIF4G), 
4E (eIF4E), and its inhibitory binding protein (4E-BP1) were 
FIGURE 1. A,B. CD46 expression on non–small-cell lung cancer cells. A, Plot of fluorescence intensity (relative to isotype) of 
cells stained with PE-labeled anti-CD46 and assessed by flow cytometry. (B) Representative histograms. LLC, murine Lewis lung 
carcinoma cell line as a negative control. (C) Plot of fluorescence intensity (relative to isotype) of cells stained with PE-labeled 
anti-Nectin-4 and assessed by flow cytometry. (D) Representative histograms. (E) Light (LM-top) and fluorescence (FM-bottom) 
microscopy of H2009 cells infected with measles virus (MV)-green fluorescent protein (GFP) after treatment with blocking 
antibodies against CD46 and nectin-4 or the combination. (F) Quantification of fluorescence after blocking CD46 and nectin-4. 
Isotype IgG and H2009 cells untreated with MV-GFP were used as positive and negative controls, respectively.
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measured to assess the effects on key proteins regulating cap-
dependent protein translation. Double-stranded RNA protein 
kinase (PKR) and its substrate, eukaryotic initiation factor 
2α (eIF2α), were assessed by immunoblot to determine the 
effects on cap-independent translational initiation (Fig. 5A). 
Expression and phosphorylation of 4E-BP1 were unchanged 
by MV infection compared with untreated cells. eIF4E was 
decreased in A549 cells after MV infection; however, it was 
unchanged in H838 and H2009. Notably, the phosphorylation 
of eIF2α was decreased in A549 and H2009 cells in response 
to MV infection. In H838 cells, the phosphorylation level of 
eIF2α was unchanged upon MV infection. Because phos-
phorylation of eIF2α results in blockade of ribosomal recruit-
ment and inhibition of translation initiation, the decreased 
FIGURE 2. A-C, Measles virus (MV) infects and lyses non–small-cell lung cancer (NSCLC) cells in vitro. A, Cell viability assay 
of cells treated with MV-green fluorescent protein (GFP) after 72 hours of treatment. Immortalized bronchial epithelial cells 
(human bronchial epithelial cells and Beas2B) are used as a nonmalignant control. MOI, multiplicity of infection. Data are 
expressed as a percentage of untreated cells. (B) Fluorescence microscopy of cells 72 hours after treatment with MV-GFP at 
multiplicity of infection of 1.0 demonstrating fluorescent syncitia. Corresponding light microscopy photographs are shown. (C) 
Human CEA measurement from supernatants of MV-infected NSCLC cells. Supernatants were collected 48 hours after infec-
tion of cells and measured by enzyme-linked immunosorbent assay assay. CEA, carcinoembryonic antigen. Error bars indicate 
standard deviation of the mean.
FIGURE 3. A, B. Measles virus (MV) infection of 
non–small-cell lung cancer (NSCLC) induces apop-
tosis. A, Immunoblot of poly-ADP ribose polymerase 
(PARP) and PARP cleavage products after 48 hours of 
treatment with MV-green fluorescent protein (GFP) 
at an multiplicity of infection (MOI) = 1.0. Presence 
of the 89 kDa fragement is indicative of apoptosis 
induction. (B) Caspase 3/7 cleavage assay done on 
NSCLC cells 48 hours after treatment with MV-GFP 
at an MOI = 1.0. Data are normalized to untreated 
NSCLC cells. Error bars indicate standard deviation 
of the mean.
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phosphorylation of eIF2α upon MV infection likely aids in 
allowing persistent viral translation. To test the potential effect 
of constitutively active eIF4F cap-dependent translational 
complex, Beas2B cells were engineered to overexpress eIF4E. 
Beas2B overexpressing eIF4E (Beas2B-E) and Beas2B trans-
fected with empty vector (Beas2B-V) were treated with MV 
and effects on viability of the cells were assayed (Fig. 5B). 
Beas2B-E was not statistically different from Beas2B-V with 
regards to cytotoxic effects of MV-GFP, though there were 
numerically less viable cells at each MOI tested. Conversely, 
pretreatment of cells with rapamycin, an mTOR inhibitor and 
known inhibitor of translation initiation, decreased virally 
mediated CEA production and resulted in less than additive 
effects compared with either treatment alone (Fig. 5C). In 
H2009, the combination of rapamycin and MV was less cyto-
toxic than rapamycin alone (p < 0.05). At MOI of 0.01, MV 
had little cytotoxic effect on H522 cells. Although the cytotox-
icity data was not significant in H522, virally mediated CEA 
production was markedly reduced as a result of prior rapamy-
cin treatment. Using MV-GFP in combination with rapamycin 
resulted in qualitatively decreased syncitia formation after 48 
hours of infection compared with MV-GFP treatment alone in 
four NSCLC cell lines (Fig. 5E). To confirm these results, a 
small molecule inhibitor of cap-dependent translation, 4EGI-
1, was used alone and in combination with MV to assess the 
effect of translation initiation on MV-mediated cytotoxicity.24 
Similarly, the combination of 4EGI-1 and MV was not statis-
tically different from either drug alone. To expand on these 
results, four NSCLC cell lines were treated with MV-GFP, 
rapamycin, or 4EGI-1 alone along with the combination of 
MV with rapamycin and MV with 4EGI-1 to formally ana-
lyze for synergy/antagonism using the method of Chou and 
Talalay.15 MV-GFP was moderate to strongly antagonistic 
with both translation inhibitors, particularly at higher MOI of 
MV-GFP used. One exception was H2030 with 4EGI-1 at the 
low dose range, which demonstrated synergy. Though transla-
tion inhibitors do not completely block viral replication, the 
above data suggest that veracity of viral oncolysis is depen-
dent upon active protein synthesis machinery.
Perhaps, the major limitation to MV for clinical transla-
tion in lung cancer is the fact that the majority of people in 
the developed world are immunized to measles by vaccination 
or previous infection. The presence of neutralizing antibodies 
could limit the ability of MV to reach sites of tumors, par-
ticularly for systemic diseases such as lung cancer. Therefore, 
suppression of the humoral immune response might be a 
reasonable way to counteract the elaboration of antibodies 
against measles. Cyclophosphamide has been successfully 
used to increase MV replication in animal toxicity studies in 
primates.25 Cyclophosphamide is not a standard therapy for 
lung cancer and therefore, it may not be an ideal drug to use 
in combination with MV for clinical translation in NSCLC. 
Gemcitabine, a nucleoside analogue, is a often used chemo-
therapeutic agent for NSCLC. In animal models, gemcitabine 
has been observed to selectively deplete B-lymphocytes and 
as a result, may decrease the humoral immune response and 
increase MV-mediated oncolysis.26 Therefore, the combina-
tion of gemcitabine and MV was assessed in vitro to indicate 
whether or not this combination was one that could be pursued 
in future clinical trials of MV for lung cancer. The combina-
tion of gemcitabine and MV resulted in additional cytotoxic-
ity compared with either treatment alone (Fig. 6). Although 
these data do not imply drug synergy between the MV and 
gemcitabine, it does indicate that in vitro, gemcitabine does 
not have a negative impact upon viral oncolysis and support 
the notion that this combination could be pursued for further 
testing in NSCLC.
DISCUSSION
Data presented here demonstrate that MV has potential 
as a therapeutic agent for patients with NSCLC. Although the 
NSCLC cell lines tested all strongly express the MV recep-
tor, CD46, there is also evidence in the literature that up to 
40% of human NSCLC specimens strongly express CD46 by 
immunohistochemistry.9 In H2009 cells, CD46 was required 
for viral entry. Blocking of CD46 resulted in near-complete 
inhibition of MV-GFP infection in H2009 cells. Though 
Edmonston-strain MV has been shown to utilize nectin-4 as 
a receptor for viral entry; the above data show that MV entry 
is not dependent upon nectin-4 expression in these NSCLC 
cells. There are potentially other mechanisms to allow viral 
entry. Recently, it has been demonstrated that MV can infect 
FIGURE 4. A-C, Measles virus (MV) oncolysis in 
non–small-cell lung cancer xenografts. A, H2009 
tumors treated for 3 weeks, twice weekly with 
MV-carcinoembryonic antigen intratumoral injec-
tions. Tumor volumes were estimated by caliper 
measurements in two dimensions. Four weeks 
after initial treatment, all mice were killed and 
tumors excised and weighed. N = 10 per group. 
(B) A549 tumors were treated as above. (C) 
Carcinoembryonic antigen enzyme-linked immuno-
sorbent assay performed on blood samples col-
lected weekly after treatment of mice bearing A549 
xenografts. Error bars depict the standard error 
of the mean. p value less than 0.05 was taken as 
significant.
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neuroblastoma cells independently of CD46 and nectin-4 
expression, though the cellular receptor in that example 
remains undefined.27 Murine cells do not express CD46 and 
we could not demonstrate evidence of infection in murine LLC 
cells (data not shown). This is at odds with recently published 
literature, which suggests antitumor activity of a different MV 
strain (Hu-191) in LLC tumors in C57/Bl6 mice.28 Although 
this data needs to be reproduced; perhaps, there is an immu-
nologic explanation for the antitumor activity separate from 
viral replication. Though CD46 expression was substantially 
greater in the cancer cells than the immortalized Beas2B cells, 
CD46 is unlikely to fully explain the tropism for cancer cells. 
H838 cells are relatively resistant to MV oncolysis despite 
possessing relatively high CD46 expression, which suggests 
that other mechanisms play a role as well.
PKR-induced eIF2α phosphorylation is one of the 
major innate cellular mechanisms to inhibit viral replica-
tion.29 Phosphorylation of eIF2α results in failure to recycle 
FIGURE 5. A–D, Effects of measles virus (MV) infection on protein translation signaling pathways. A, H2009, A549, and H838 
cell lysates were assayed by immunoblot before and 48 hours after infection with MV-green fluorescent protein (GFP) for key 
proteins involved in cap-dependent and independent translation initiation. (B) Beas2B expressing empty vector (Beas2B-V) and 
Beas2B expressing eIF4E (Beas2B-E) were infected with MV-carcinoembryonic antigen (CEA) at indicated MOI and assayed for 
cell viability 72 hours after infection. 5′ cap-affinity assay of untreated Beas2B-V and Beas2B-E are shown. Relative increases in 
eIF4G binding in the cap-affinity assay correspond to enhanced eIF4F cap-complex formation. (C) H2009 and H522 non–small-
cell lung cancer (NSCLC) cells were treated with MV-CEA (MOI = 0.01), rapamycin (Rap), or the combination and assayed for 
cell viability 72 hours after infection. Supernatants were collected from cells and assayed for CEA production as a measure of 
viral replication. Error bars indicate standard deviation of the mean. * indicates statistical significance. (D) H2009 and H522 cells 
were treated with MV-CEA (multiplicity of infection [MOI] = 0.01), 4EGI-1 (15 μM), or the combination and cell viability assayed 
72 hours after infection. (E) NSCLC cell lines were treated with MV-GFP at MOI of 0.25 either alone or in combination with 
rapamycin. Representative fluorescence micrographs are shown.
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eukaryotic translation initiation factors and results in a global 
decrease in protein synthesis.30 H2009 and A549 cells that are 
quite sensitive to measles oncolysis in vitro show near-com-
plete dephosphorylation of eIF2α in response to MV infec-
tion. There was virtually no change in eIF2α phosphorylation 
in the relatively resistant H838. This may explain, in part, the 
relative resistance of H838 cells to MV-mediated lysis. On the 
other hand, the apoptosis data suggest that H838 cells may not 
fully be able to execute the apoptotic program after MV infec-
tion, which also may be playing a role in development of resis-
tance to this therapy. These conclusions are purely speculative 
and further work will be required to determine if these mecha-
nisms are truly playing a role in resistance to MV therapy.
Previous literature indicates that NSCLC have constitu-
tive activation of cap-dependent translation.23 Overexpression 
of eIF4E, and constitutive activation of eIF4F complex, had 
an insignificant impact upon MV oncolysis of Beas2B cells. 
However, the combination of MV with rapamycin and 4EGI-1 
resulted in moderate to strong antagonism. The combination of 
MV and rapamycin resulted in inhibition of viral expression 
of CEA, and decreased syncitia when infected with MV-GFP. 
FIGURE 6.  Measles virus (MV) combined with gemcitabine 
results in enhanced cytotoxicity. H522 and H2009 cells were 
treated with MV (multiplicity of infection = 0.1), gemcitabine 
(25 nM), or the combination. Cells were assayed 72 hours 
after MV infection for viability by trypan blue exclusion. Error 
bars indicate standard deviation of the mean.
TABLE 1.  Combination Index for MV-GFP and Translation Inhibitors
H2030 H2009
MV (MOI) Rapamycin (nM) Combination Index MV (MOI) Rapamycin (nM) Combination Index
0.1 1 5.48 0.1 1 3.96
0.1 10 8.41 0.1 10 7.99
0.1 50 8.5 0.1 50 5.03
0.25 1 236 0.25 1 57.6
0.25 10 46.7 0.25 10 35.9
0.25 50 49,952 0.25 50 540.7
MV (MOI) 4E-GI-1 (μm) Combination Index MV (MOI) 4E-GI-1 (μM) Combination Index
0.1 1 17 0.1 1 9.419
0.1 10 1.07 0.1 10 12.299
0.1 50 2.41 0.1 50 460,918
0.25 1 0.11 0.25 1 1.72
0.25 10 0.54 0.25 10 173
0.25 50 2.67 0.25 50 2.73E+14
A549 H522
MV (MOI) Rapamycin (nM) Combination Index MV (MOI) Rapamycin (nM) Combination Index
0.1 1 1.55 0.1 1 0.79
0.1 10 0.59 0.1 10 0.77
0.1 50 3.08 0.1 50 1.15
0.25 1 0.957 0.25 1 1.49
0.25 10 1.22 0.25 10 1.29
0.25 50 1.93 0.25 50 1.53
MV (MOI) 4E-GI-1(μM) Combination Index MV (MOI) 4E-GI-1 (μM) Combination Index
0.1 1 1.02 0.1 1 1.22
0.1 10 1.89 0.1 10 2.26
0.1 50 1.79 0.1 50 1.1
0.25 1 1.23 0.25 1 1.2
0.25 10 1.72 0.25 10 2.17
0.25 50 1.67 0.25 50 1.36
MV, measles virus; GFP, green fluorescent protein; MOI, multiplicity of infection.
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Though the data presented cannot exclude the role of other 
defects in innate antiviral defenses, they are suggestive that 
translational control plays a role in MV oncolysis. These results 
are consistent with observed effects in mesothelioma cells.31
Based on the exquisite sensitivity of A549 cells in vitro 
to MV infection, the A549 xenograft results were somewhat 
unexpected. There was a trend toward the end of the experi-
ment toward smaller tumors in the treated animals, and there-
fore, it is possible that longer observation may have been 
required to see a larger effect. Analysis of CEA in the serum 
indicates that MV was able to continue to replicate throughout 
the experiment. It has been observed that viral spread within 
A549 tumors might be limited by murine stromal elements 
when treated by intratumoral injection of oncolytic adeno-
virus.32 Like adenovirus, MV does not infect murine tissues 
and therefore, could be inhibited by a similar mechanism. 
Interestingly, recent work has delineated a potentially impor-
tant role for tumor stromal elements in limiting viral spread 
that can be modified using angiotensin receptor blockers.33
There are several caveats to the translation of these 
findings to the clinical setting. First, the majority of patients 
in the developed world has been vaccinated against MV, and 
therefore has circulating antibodies that can limit therapy with 
MV. The in vitro and immune deficient mouse models do not 
take this potential obstacle into account. Because mice lack 
the MV receptor and are not natural hosts to MV infection, 
use of known immune competent mouse models of lung can-
cer are precluded. For lung cancer, in particular, intratumoral 
injection may not be feasible in clinical practice for a disease 
that is hallmarked by bloodborne metastasis. Experience 
with systemic delivery indicates that immune suppression 
to decrease neutralizing antibodies may be more efficacious. 
Cyclophosphamide treatment blocks the humoral immune 
response and results in higher titer and longer duration of 
MV viremia in primates, and cyclophosphamide treatment 
with MV therapy is being tested for patients with multiple 
myeloma.34 Gemcitabine has been observed to result in similar 
inhibition of the humoral immune response, and therefore is a 
potentially useful drug to use in combination, as it is a clini-
cally active drug against NSCLC. In support of this hypoth-
esis, a recent clinical trial of oncolytic reovirus in combination 
with gemcitabine resulted in a muted neutralizing antibody 
response.35 In vitro, MV cytotoxicity is not inhibited by con-
comitant treatment of NSCLC cells with gemcitabine. Thus, 
our results support the clinical translation of MV in combina-
tion with gemcitabine for patients with NSCLC. Because of 
the limited host range of MV, this question will be difficult to 
study further in lung cancer animal models.
In summary, these data suggest a potential role of MV 
in treatment of NSCLC. Further investigation will be required 
to evaluate the potential of systemic administration of MV and 
strategies to enhance viral delivery to tumors in the setting of 
neutralizing antibodies. A phase I study utilizing MV as a can-
cer therapy has now been completed and three others are ongo-
ing, including intravenous delivery for patients with myeloma. 
Thus far, the treatment has been exceedingly safe. NSCLC is 
the leading cause of cancer death worldwide. Further develop-
ment of this novel form of therapy for NSCLC is warranted.
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